Financial Performance - The company's operating revenue for 2024 is expected to be ¥119,001,736.41, a decrease of 28.16% compared to the previous year[4] - The net profit attributable to shareholders is projected to be -¥58,000,034.21, reflecting a decline of 392.25% year-on-year[4] - The basic earnings per share is projected to be -0.68, a decline of 385.71% year-on-year[4] Assets and Equity - Total assets at the end of the reporting period are estimated to be ¥444,363,639.12, down 8.14% from the beginning of the period[6] - Shareholders' equity attributable to the company is expected to be ¥230,980,454.37, a decrease of 20.07% compared to the start of the period[6] Market Challenges - The decline in revenue is attributed to a downturn in the MRI equipment market and challenges in market expansion[7] - The company is in the early stages of establishing its brand in the MRI equipment market, which has affected its market penetration[7] Operating Expenses - Increased operating expenses due to investments in marketing, research, and development have negatively impacted net profit[8] - Inventory impairment losses and intangible asset impairment losses have increased due to the significant drop in revenue[9] Cautionary Notes - The financial data presented is preliminary and subject to final confirmation in the annual report, highlighting the need for cautious investment decisions[10]
辰光医疗(430300) - 2024 Q4 - 年度业绩